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Abstract
Objective: To determine if cervical ripening with the prostaglandin E2 analogue dinoprostone effectively shortens the induction- 
to-delivery interval in midpregnancy terminations with sulprostone. Study design: We retrospectively studied 100 women admitted 
for pregnancy termination at midgestation because of fetal anomalies between September 1989 and January 1993. Three regimens 
were used: 27 women received intramuscular sulprostone only, 29 women received intravenous sulprostone only, and 44 women 
received intravenous sulprostone after cervical priming with dinoprostone. Wilcoxon’s rank sum test was used for statistical analy­
sis. Results: Dinoprostone priming did not significantly reduce the induction-to-delivery interval in either parous or nulliparous 
women. However, when divided into first and subsequent pregnancies, we found that primigravidae, but not multigravidae, had 
an induction-to-delivery interval that was significantly shorter by approximately 10.5 h when pretreated with dinoprostone. Conclu­
sion: Dinoprostone priming of the cervix prior to termination of midgestation pregnancy with sulprostone (Nalador) effectively 
shortens the induction-to-delivery interval in women in their first pregnancy.
Keywords: Sulprostone; Prostaglandin; Second trimester abortion; Pregnancy termination; Dinoprostone; Midgestation ter­
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1. Introduction
Termination o f second trimester pregnancy for fetal 
anomalies is commonly carried out in Europe with the 
use o f the prostaglandin analogue, 16-phenoxy-17,18, 
19,20 tetranor PG E2 methylsulphonamide (sulprostone, 
Nalador®). Sulprostone can either be given as con­
tinuous intravenous infusion or by repeated in tra­
muscular injections. Because continuous intravenous in­
fusion is easier to  control, produces less side effects and 
requires a lower total dose, continuous intravenous infu­
sion has replaced intram uscular injections in recent 
years [1],
Cervical application o f  prostaglandin E2 (dinopro­
stone, Cerviprost®) has been used both for ripening o f 
the cervix prior to induction o f labour at term  [2] and
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prior to first trimester term ination o f pregnancy [3]. 
Based on the idea that intracervical dinoprostone might 
facilitate term ination o f second trimester pregnancy 
with the use o f sulprostone, and some encouraging 
earlier reports [4-6], patients who were adm itted for ter­
mination o f midgestation pregnancy with sulprostone 
were routinely pretreated with dinoprostone at our De­
partm ent o f Gynaecology from July 1991 onwards.
To evaluate if priming o f the cervix with dinoprostone 
indeed effectively shortens the time to  delivery o f the 
fetus after the initiation o f sulprostone administration, 
we retrospectively analysed the data o f women admitted 
for termination o f pregnancy.
2. Materials and methods
In a retrospective study we analysed the data o f 100 
consecutive women who were adm itted for term ination 
o f pregnancy on the basis o f  structural and chromo-
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somal fetal anomalies at the University Hospital, R ot­
terdam. In the period from September 1989 to  January 
1993, three different regimens were used in a more or 
less chronological order: (1) Repeated intram uscular in­
jections of sulprostone, at the rate o f one injection of 
500 ng  every 4 h for 24 h, followed by a sulprostone-free 
interval o f 24 h. This regimen was repeated until deliv­
ery; (2) Continuous intravenous infusion o f  sulprostone 
at the rate of 2 /tg/min for 24 h, followed by a 
sulprostone-free interval o f 24 h. This regimen was re­
peated until delivery; (3) Continuous intravenous infu­
sion of sulprostone identical to Regimen 2 was initiated 
12-16 h after a single intracervical dose o f 0.5 mg 
dinoprostone, if the patient had not delivered within 
that time.
We studied the interval between initiation o f  sulpros­
tone therapy and the expulsion o f  the fetus for the three 
regimen groups. We performed two analyses: one based 
on a division according to  parity and one based on a di­
vision into primigravidae vs. multigravidae. We report 
median values and ranges, and we used the W ilcoxon’s 
rank sum test and the Chi-square test for statistical anal­
ysis. A P-value o f <  0.05 was taken as the level o f signif­
icance.
3. Results
A total o f 100 women were adm itted to  the University 
Hospital, Rotterdam , for term ination o f midgestation 
pregnancy after diagnosis o f a congenital anomaly of the 
fetus. From  September 1989 until July 1991, Regimen 1 
or 2 were used in 56 o f  these patients, 19 nulliparae and 
37 parae; from July 1991 until January 1993 Regimen 3 
was used in 44 patients, 22 nulliparae and 22 parae. All 
patients who underwent term ination delivered vaginally 
without m ajor side effects o f the medication, o r any 
other major complication.
Table 1 shows the differences in gestational age and 
interval between the initiation o f sulprostone treatment 
and delivery, according to parity and regimen. There 
were no significant differences in gestational age be­
tween subgroups. The induction-to-delivery interval was 
lower in parous than in nulliparous women (by approx­
imately 8.5 h). The difference in interval between parous 
and nulliparous women was significant in the women 
treated with sulprostone only (approximately 10 h), but 
not in those women pretreated with dinoprostone (ap­
proximately 4.5 h). In the dinoprostone pretreated 
group two women (one nullipara and one para) deliv­
ered before sulprostone induction was initiated. 
Although the women who were pretreated with 
dinoprostone tended to have shorter intervals than the 
women who were treated with sulprostone only (by ap­
proximately 8 h for nulliparae and 2 h for parae), these 
differences were not significant, both compared to sul­
prostone i.v. only and to sulprostone i.v. and i.m. com­
bined, due to m arked variation between individuals.
O f the total group o f 41 nulliparae, 31 were 
primigravida at the time o f pregnancy term ination and 
10 were in their second or subsequent pregnancy. O f 
these women, one had a spontaneous abortion plus 
dilatation and curettage, four women had an elective 
abortion through vacuum curettage, one woman had a 
previous midgestation term ination with sulprostone; the 
other women had a history o f a combination o f these.
Table 2 shows the differences in gestational age and 
induction-to-delivery interval, according to gravidity 
and regimen. There were no significant differences in 
gestational age between subgroups. The induction-to- 
delivery interval was significantly shorter in multi­
gravidae than in primigravidae by approximately 7 h. 
The difference in interval between multigravidae and 
primigravidae was significant in the women treated with 
sulprostone only (approximately 10 h), but not in those
Table 1
Differences in gestational age and the interval between initiation o f  sulprostone treatm ent and delivery, for nulliparae and parae
Sulprostone i.m. Sulprostone i.v. D inoprostone + sulprostone i.v. Total
Nulliparae
N um ber 9 10 22 41
G estational age (weeks) 18 5/7 18 0/7 19 2/7 19 0/7
(15 6 /7 -23  0/7) (14 1/7-22 5/7) (15 0 /7 -23  2/7) (14 1/7-23 2/7)
Interval to delivery (h) 23.25 (9.38-47.08) 23.63 (8.92-70.83) 15.58 (0.00-88.17) 21.00 (0.00-88.17)
Parae ■
Num ber 18 19 22 59
Gestational age (weeks) 18 4/7 18 6/7 18 4/7 18 5/7
(13 4/7-21 0/7) (15 6 /7-23 0/7) (14 0 /7 -22  5/7) (13 4 /7 -23  0/7)
Interval to  delivery (h) 13.92* (3.25-42.58) 12.92* (5.25-62.75) 11.00 (0.00-71.50) 12.55* (0.00-71.50)
M edian value with ranges in brackets.
*P  <  0.05 com pared with nulliparae. N o  significant differences between treatm ent groups.
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Table 2
Differences in gestational age and the interval between initiation o f  sulprostone treatm ent and delivery, for prim igravidae and m ultigravidae
Sulprostone i.m. Sulprostone i.v. D inoprostone + sulprostone i.v. Total
Primigravidae
Num ber 8 8 15 31
G estational age (weeks) 18 5/7 18 5/7 19 2/7 19 0/7
(15 6 /7-23 0/7) (15 0 /7 -22  5/7) (15 0 /7 -23  2/7) (15 0 /7-23 2/7)
Interval to  delivery (h) 23.13 (9.38-47.08) 24.67 (8.92-70.83) 14.00* (0.00-88.17) 19.75 (0.00-88.17)
Multigravidae
Num ber 19 21 29 69
G estational age (weeks) 18 4/7 18 5/7 18 6/7 18 5/7
(13 4/7-21 0/7) (14 1/7-23 0/7) (14 0 /7-23 0/7) (13 4 /7 -23  0/7)
Interval to  delivery (h) 14.33** (3.25-42.58) 12.92** (5.25-62.75) 13.00 (0.00-71.50) 13.00**
(0.00-71.50)
Median value w ith ranges in brackets.
*P <  0.05 com pared with sulprostone only. 
**P <  0.05 com pared with primigravidae.
women pretreated with dinoprostone (approximately 1 
h). In the dinoprostone pretreated group, two women 
(one primigravida and one multigravida) delivered 
before sulprostone induction was initiated. In primi­
gravidae who received pretreatm ent with dinoprostone, 
the induction-to-delivery interval was significantly 
reduced (by approximately 10.5 h) as compared to 
women who received sulprostone only, both compared 
to sulprostone i.v. only and to  sulprostone i.v. and i.m. 
combined. In multigravidae, pretreatm ent with dino­
prostone did not result in a significant reduction o f the 
induction-to-delivery interval.
Seventy-eight women, 28 o f 41 nulliparae (68%) and 
50 of 59 parae (85%), 21 o f 31 primigravidae (68%) and 
57 o f 69 (83%) multigravidae, delivered within 24 h after 
initiation o f sulprostone treatment. A significantly 
higher percentage o f  nulliparous women delivered <  24 
h after initiation o f sulprostone treatm ent following 
dinoprostone priming (18/22, 82%) than w ithout prim ­
ing (10/19, 53%). Similarly, a significantly higher percen­
tage o f primigravidae delivered <  24 h after initiation of 
sulprostone priming (13/15, 87%) than without priming 
(8/16, 50%). D inoprostone priming had no significant 
effect on the chance to deliver <  24 h after the initiation 
of sulprostone treatm ent in parae and multigravidae.
4. Discussion
If  it is necessary to  terminate a pregnancy in midgesta­
tion, it is desirable that the technique of term ination is 
optimally effective, with minimal side effects. Therefore, 
the duration o f hospital admission and the interval from 
initiation of treatm ent to  delivery should be as short as 
possible. In addition, a recent study has shown that an 
infusion rate o f sulprostone half that o f which was used
in the present study is also effective [1], A lthough the in­
tramuscular route o f sulprostone is no longer used be­
cause o f the risk o f overdosage, our study shows that 
intramuscularly and intraveneously administered sul­
prostone are equally effective.
In term pregnancies, ripening o f  the cervix with local­
ly applied prostaglandin E2 facilitates induction o f  la­
bour and reduces the induction-to-delivery interval [2], 
It is not well known whether this also applies to midterm 
pregnancy. Several investigators have attem pted to im­
prove upon the technique o f  midgestation term ination 
with the use o f prostaglandins, and report a favorable 
effect of pretreatm ent either through vaginal application 
o f prostaglandin E2 tablets [4] or cervical application of 
sulprostone gel, prostaglandin E2 or F 2„ gel [5,6]. How­
ever, these studies all lack a control group, which limits 
their importance.
We found that the induction-to-delivery interval after 
sulprostone in midgestation is much shorter in multi­
gravidae and parae compared to  primigravidae and 
nulliparae. Apparently, the cervix dilates more easily 
after it has been previously dilated. Given the already 
short induction-to-delivery interval in multigravidae 
and parae it may not be surprising that the interval is 
not significantly shortened any further by pretreatm ent 
of the cervix with a locally applied, but weaker, pro­
staglandin analogue.
O ur observation that pretreatm ent with dinoprostone 
does significantly reduce the induction-to-delivery inter­
val in primigravidae but not in nulliparae suggests that 
it makes little difference as to  how the cervix has 
previously been artificially dilated. Because all o f the 10 
multigravidae nulliparae had experienced an artificial 
type o f dilatation, it is uncertain to  what extent a pre­
vious spontaneous abortion alone, w ithout dilatation,
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might affect the response to dinoprostone pretreatm ent 
in a subsequent pregnancy.
Although only a prospective, placebo-controlled, ran­
domized trial can answer definitively the question to 
what extent cervical priming with dinoprostone shortens 
the induction-to-delivery interval in midpregnancy ter­
mination with sulprostone, our retrospective study 
strongly suggests that pretreatm ent with dinoprostone is 
indeed effective in primigravidae. When dinoprostone 
on this indication is administered on an outpatient basis, 
in primigravidae the duration o f  hospitalization for sul­
prostone termination in midpregnancy can be reduced.
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